CERo Therapeutics (CERO) News Today $6.87 -0.44 (-6.02%) Closing price 03:59 PM EasternExtended Trading$7.96 +1.09 (+15.88%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cero Therapeutics announces 1-for-20 reverse stock splitJune 12, 2025 | finance.yahoo.comCERo Therapeutics announces 1-for-20 reverse stock split effective June 13June 11, 2025 | msn.comCERo Therapeutics Holdings, Inc. Announces One-for-Twenty Reverse Stock Split Effective June 13, 2025June 11, 2025 | quiverquant.comCERo Therapeutics Holdings, Inc. Announces Reverse Stock SplitJune 11, 2025 | globenewswire.comCERo Therapeutics issues additional Series D stockJune 7, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 MillionJune 6, 2025 | quiverquant.comCERo Therapeutics, Inc. Announces Option Exercise for Additional Series D FinancingJune 6, 2025 | globenewswire.comCERo Therapeutics secures key patents for cancer therapyJune 4, 2025 | uk.investing.comCERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy PortfolioJune 4, 2025 | nasdaq.comCero announces two granted U.S. patents, European patent application allowanceJune 4, 2025 | finance.yahoo.comCero announces two granted U.S. patents, European patent application allowanceJune 4, 2025 | finance.yahoo.comMaxim Group Maintains Buy Rating on CERo Therapeutics (CERO)June 2, 2025 | insidermonkey.comCERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236June 2, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML TrialMay 31, 2025 | insidermonkey.comD. Boral Capital Downgrades CERo Therapeutics Holdings (CERO)May 30, 2025 | msn.comCERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined EvaluationsMay 30, 2025 | globenewswire.comMaxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy RecommendationMay 20, 2025 | msn.comCERo Therapeutics regains Nasdaq compliance, eyes trialsMay 9, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | globenewswire.comCERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid LeukemiaMay 3, 2025 | nasdaq.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical ...April 30, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical ...April 30, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 30, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER ...April 26, 2025 | seekingalpha.comCERo Therapeutics Announces Clinical Trial Partnership with Sarah Cannon Research Institute for Phase 1 Trial of CER-1236 in Acute Myeloid LeukemiaApril 26, 2025 | nasdaq.comCero Therapeutics to present on CER-1236 at ASCO meetingApril 26, 2025 | markets.businessinsider.comCERo announces SCRI as main site for trial of CER-1236 to treat AMLApril 26, 2025 | msn.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American ...April 25, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American ...April 25, 2025 | gurufocus.comCero Therapeutics announces SCRI at CBCI as key trial site for Phase 1 trialApril 25, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingApril 25, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 24, 2025 | globenewswire.comCERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy ProgramsApril 23, 2025 | nasdaq.comCero Therapeutics initiated with a Buy at D. Boral CapitalApril 23, 2025 | markets.businessinsider.comCero Therapeutics enters securities purchase agreement for up to $8MApril 23, 2025 | markets.businessinsider.comD. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy RecommendationApril 22, 2025 | msn.comCERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy DevelopmentApril 22, 2025 | quiverquant.comCERo Therapeutics, Inc. Announces Up to $8 Million Series D FinancingApril 22, 2025 | globenewswire.comCERo Therapeutics expands patent portfolio with new US approvalsApril 12, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236April 12, 2025 | seekingalpha.comCero Therapeutics announces critical patent application allowances from USPTOApril 10, 2025 | markets.businessinsider.comCero announces initial clinical trial site for Phase 1 trial of CER-1236April 10, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. ...April 10, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236April 10, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236April 10, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 9, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 9, 2025 | globenewswire.comCERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid TumorsApril 2, 2025 | nasdaq.comCero Therapeutics receives FDA clearance of second IND application for CER-1236April 1, 2025 | markets.businessinsider.com Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address CERO Media Mentions By Week CERO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERO News Sentiment▼0.810.90▲Average Medical News Sentiment CERO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERO Articles This Week▼62▲CERO Articles Average Week Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UBX News BTAI News TRIB News ERNA News BCDA News BGXX News GLYC News CSCI News ORGS News PHXM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERO) was last updated on 6/16/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
